In Vivo Gene Editing Therapies Offer Root-Cause Treatment for Genetic Diseases, but Efficient and Precise Liver-Targeted Delivery Remains a Critical Hurdle for Clinical Translation. Lipid Nanoparticles (LNPs), as the Mainstream Non-Viral Vector, Have Made Functionalization a Core Strategy for Enhancing Targeting Efficiency. Xiamen Sinopeg Biotech Co., Ltd. (Sinopeg) is proud to introduce its independently innovated structure,GalNAc-PEG-DTA-5-2K. This liver-targeting functional PEG lipid, specifically designed for LNP systems, aims to provide gene editing and siRNA drug developers with a high-performance excipient option featuring a clear IP profile. It is set to empower the advancement of liver-targeted therapeutic pipelines. I. Delivery Challenges for Liver-Targeted Gene Editing The in vivo application of gene editing therapies hinges on the safe and precise delivery of the CRISPR system (editor mRNA and guide RNA) to target cells. LNPs have become a recognized in vivo delivery platform, owing to their excellent encapsulation and protection capabilities, low immunogenicity, and scalability for manufacturing. However, after intravenous administration, conventional LNPs are largely cleared by liver immune cells or degraded in circulation, with a limited fraction reaching hepatocytes. This restricts therapeutic efficacy and may increase off-target risks. Thus, endowing LNPs with active liver-targeting capabilities is an inevitable direction for technological advancement. Among targeting strategies, the N-acetylgalactosamine (GalNAc) ligand stands out as a well-established and extensively validated liver-targeting approach. Its receptor, the asialoglycoprotein receptor (ASGPR), is highly expressed on the surface of hepatocytes and is not found at significant levels in other tissues. This makes the GalNAc-ASGPR pathway a highly efficient and specific natural targeting mechanism. GalNAc ligands can specifically bind to ASGPR, facilitating efficient cellular uptake via receptor-mediated endocytosis. Integrating this strategy into LNP systems offers a new design dimension for the hepatic delivery of gene editing drugs. II. Industry Trend: GalNAc-PEG Lipids Emerge as a Consensus Direction for Liver-Targeted LNPs In the field ofin vivogene editing, cutting-edge research from both international and domestic fronts is converging on the GalNAc-PEG lipid technology pathway. U.S.-based Verve Therapeutics, in its second-generationin vivobase editing therapy, has incorporated GalNAc targeting ligands into its LNP delivery system, modifying the LNP surface with GalNAc-containing PEG lipids. This upgrade aims to enhance liver targeting, increase drug concentration within hepatocytes, thereby achieving effective editing at lower doses and improving drug tolerability and safety. Drawing on clinical experience from its first-generation product, Verve has made a clear targeted enhancement to its delivery vehicle, reflecting that GalNAc-LNPs have become a technological...

Join Us at CPHI China 2026! SINOPEG's booth no. W4F66 Exciting news! CPHI China 2026 is just around the corner, taking place June 16–18 at the Shanghai New International Expo Centre. SINOPEG will be showcasing cutting-edge drug delivery system (DDS) solutions at Booth W4F66. As your trusted partner in specialty chemicals and advanced drug delivery systems, we’re eager to share innovations that drive industry progress. Why visit us? Explore our latest portfolio of PEG derivatives, lipids, and custom synthesis services Discuss tailored solutions for your R&D and manufacturing challenges Connect face-to-face with our technical experts We warmly welcome friends, partners, and industry peers from around the globe to drop by! Let’s collaborate to shape the future of pharma. Dates: June 16–18, 2026 Venue: Shanghai New International Expo Centre Our Booth: W4F66 (Hall W4) Ready to meet? Simply stop by!

Join Us at TIDES USA 2026 in Hynes Convention Center! Mark your calendars! TIDES USA 2026—the premier event for oligonucleotide and peptide therapeutics—is coming to Boston, MA, on May 11-14, 2026. Visit Sinopeg at Booth #1010 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global mRNA vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #1010. #TIDES2026 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Spring brings another good news! Following the European patent allowance for cationic lipids in February 2026, our patent portfolio has achieved another milestone. In April 2026, several cationic lipid products independently developed by Sinopeg—including DHA-1, SNP24-1, SNP25-1, and SNP26-1—successfully received U.S. patent allowance, protected in the form of a Markush formula. With this, the DHA-1 series cationic lipids have now secured patent coverage in the three core markets of China, Europe, and the United States, establishing a global intellectual property moat for this key excipient of LNP delivery systems. Patent Title: Cationic Lipid, Liposome Containing Cationic Lipid, and Nucleic-Acid Pharmaceutical Composition Containing Liposome and Formulation and Application Thereof Patent Application No.: 18/269,728 Applicant: Xiamen Sinopeg Biotech Co., Ltd. Source: Notice of Allowance from the USPTO (screenshot) Patent Breakthrough: Comprehensive Coverage from China to Europe and the U.S. DHA-1, SNP24-1, SNP25-1, SNP26-1, and others are cationic lipids independently developed by Sinopeg. They feature high biocompatibility and high transfection efficiency, effectively bypassing existing patent restrictions and providing a reliable, localized alternative for the LNP delivery field. In terms of IP strategy, the patent journey for the DHA-1 series has been solid and methodical: September 2022: Granted Chinese patent (priority application). October 2023: Granted patent for PCT national phase entry in China. February 2026: Granted European patent, achieving full coverage in China and Europe. April 2026: Granted U.S. patent, protected in Markush formula form. Thus, the DHA-1 series cationic lipids now hold patent protection in all three major markets—China, Europe, and the U.S.—providing a strong legal foundation for compliant commercialization and global business expansion. Beyond patent coverage, DHA-1 also leads in regulatory compliance: it has successfully completed CDE pharmaceutical excipient filing in China (Filing No. F20230000445) and has submitted a U.S. FDA DMF (Filing No. 039452). Customers can directly reference Sinopeg's filed dossiers in both China and the U.S., significantly reducing submission preparation time and accelerating project progress. Markush Formula Allowance: Broader Protection, Stronger Barrier What is a Markush formula allowance, and how is it different from a standard compound patent? Simply put, the Markush formula is one of the most valuable forms of patent protection in the pharmaceutical compound field. It uses a "generic formula" approach, covering a class of compounds that share a common structure and similar properties, rather than protecting only a single structure. For this series of cationic lipids, this means: Broader protection – The patent covers not only the dozens of specific structures exemplified (including DHA-1, SNP24-1, SNP25-1, SNP26-1) but also other cationic lipid structures sharing the same core ...

As we prepare to welcome a season of strength, speed, and success, our team will be taking a short break to celebrate the Chinese New Year with our loved ones. Holiday Notice: We will be closed from February 15 to February 23. Normal business operations will resume on February 24. During this period, if you have any urgent inquiries or project needs, please feel free to: Leave us a message via our website: www.sinopeg.com Or email us at: sales@sinopeg.com We’ll get back to you promptly upon our return. Wishing you and your family a joyful, prosperous, and horse-powered New Year! #ChineseNewYear #YearOfTheHorse #SpringFestival #HolidayNotice #GlobalBusiness #Sinopeg #ClientCare #NewYear2026